ZFIN ID: ZDB-FIG-210518-96
Oprişoreanu et al., 2021 - Automated in vivo drug screen in zebrafish identifies synapse-stabilising drugs with relevance to spinal muscular atrophy. Disease models & mechanisms   14(4) Full text @ Dis. Model. Mech.
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Gene:
Fish:
Conditions:
Anatomical Term:
Stage: Prim-5
PHENOTYPE:
Fish:
Conditions:
Observed In:
Stage: Prim-5

Fig. 6. (A) Representative images of the lateral trunk of 28-30 hpf wild-type embryos. Abnormal motor neurons, i.e. short, missing or branched axons, are indicated by arrowheads. (B) The percentage of abnormal motor axons is decreased in embryos after combined treatment with UBEI-41 and dipyridamole (10 µM each) compared to those treated with UBEI-41 alone (Kruskal–Wallis test ****P<0.0001 with Dunn's multiple comparison test: ****P<0.0001, **P=0.0078 *P=0.0124, statistical power=0.999). (C) Representative images of 28-30 hpf wild-type embryos treated with DMSO, UBEI-41 or UBEI-41 and dipyridamole are shown. Abnormal axon branching is indicated by black arrowheads. Scale bars: 50 µm. (D) Quantification of axonal branching only. The number of axon branches is increased in embryos after treatment with dipyridamole (10 µM) compared to those treated with DMSO (control) (one-way ANOVA test ***P=0.0006 with Tukey's multiple comparison test: ***P=0.0007, **P=0.0062 statistical power=0.9618). All scale bars: 50 µm. Each data point represents one animal and n numbers are indicated in parenthesis. Error bars represent means±s.e.m.

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
GFP ml2Tg control Prim-5 CaP motoneuron axon IFL
ml2Tg chemical treatment by environment: PYR-41 Prim-5 CaP motoneuron axon IFL
ml2Tg chemical treatment by environment: dipyridamole, chemical treatment by environment: PYR-41 Prim-5 CaP motoneuron axon IFL
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
ml2Tg chemical treatment by environment: PYR-41 Prim-5 CaP motoneuron axon extension decreased process quality, abnormal
Prim-5 CaP motoneuron axon increased branchiness, abnormal
Prim-5 CaP motoneuron collateral sprouting increased occurrence, abnormal
ml2Tg chemical treatment by environment: dipyridamole, chemical treatment by environment: PYR-41 Prim-5 CaP motoneuron axon branchiness, ameliorated
Prim-5 CaP motoneuron axon extension process quality, ameliorated
Prim-5 CaP motoneuron collateral sprouting process quality, ameliorated
Acknowledgments:
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Dis. Model. Mech.